AR085090A1 - Formulacion transdermica de testosterona, metodo de tratamiento - Google Patents
Formulacion transdermica de testosterona, metodo de tratamientoInfo
- Publication number
- AR085090A1 AR085090A1 ARP120100241A ARP120100241A AR085090A1 AR 085090 A1 AR085090 A1 AR 085090A1 AR P120100241 A ARP120100241 A AR P120100241A AR P120100241 A ARP120100241 A AR P120100241A AR 085090 A1 AR085090 A1 AR 085090A1
- Authority
- AR
- Argentina
- Prior art keywords
- weight
- formulation
- long chain
- chain fatty
- testosterone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Dispersion Chemistry (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Pregnancy & Childbirth (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Reivindicación 1: Una formulación transdérmica o a través de mucosa que comprende: 2% de peso de testosterona, Alcanol C2-4, polialcohol, y éter monoalquilo de dietilenglicol, en donde la mencionada formulación está sustancialmente libre de alcoholes grasos de cadena larga, ácidos grasos de cadena larga y ésteres grasos de cadena larga.Reivindicación 20: Una formulación transdérmica o a través de mucosa que comprende: 2% peso de testosterona, 44.0% peso de etanol, 20.0% peso de propilenglicol, 5.0% peso de éter monoetilo de dietilenglicol, 1.20% peso de carbómero, 0.35% peso de trietanolamina, 0.06% peso de disodio edetato y agua en donde la mencionada formulación está sustancialmente libre de alcoholes grasos de cadena larga, ácidos grasos de cadena larga y ésteres grasos de cadena larga. Reivindicación 22: Una formulación de cualquiera de las reivindicaciones 1 a 21, en donde la mencionada formulación está en la forma de un gel, loción, crema, atomizador, aerosol, ungüento, emulsión, suspensión, sistema de liposomas, laca, parche, venda, tableta bucal, tableta sublingual, supositorio, forma de dosis vaginal o vendaje oclusivo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11152210 | 2011-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085090A1 true AR085090A1 (es) | 2013-09-11 |
Family
ID=44146428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100241A AR085090A1 (es) | 2011-01-26 | 2012-01-25 | Formulacion transdermica de testosterona, metodo de tratamiento |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8895053B2 (es) |
| EP (2) | EP2667851B1 (es) |
| JP (2) | JP6012632B2 (es) |
| KR (1) | KR101877476B1 (es) |
| CN (1) | CN103327962B (es) |
| AR (1) | AR085090A1 (es) |
| AU (1) | AU2012210691B2 (es) |
| BR (1) | BR112013018951B1 (es) |
| CA (1) | CA2824941A1 (es) |
| DK (2) | DK3072505T3 (es) |
| ES (2) | ES2741744T3 (es) |
| HK (1) | HK1192719A1 (es) |
| HR (2) | HRP20160887T1 (es) |
| HU (3) | HUE044327T2 (es) |
| IL (1) | IL227454A (es) |
| JO (1) | JO3755B1 (es) |
| LT (2) | LT3072505T (es) |
| MX (1) | MX340259B (es) |
| PL (2) | PL2667851T3 (es) |
| PT (2) | PT3072505T (es) |
| RS (2) | RS54898B1 (es) |
| RU (1) | RU2613891C2 (es) |
| SA (1) | SA112330224B1 (es) |
| SI (2) | SI3072505T1 (es) |
| TR (1) | TR201909271T4 (es) |
| TW (1) | TWI564029B (es) |
| WO (1) | WO2012101016A1 (es) |
| ZA (1) | ZA201305665B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| TWI442932B (zh) | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法 |
| CN102421414A (zh) * | 2009-05-01 | 2012-04-18 | 辉凌公司 | 用于治疗前列腺癌的组合物 |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| ES2617336T3 (es) | 2010-10-27 | 2017-06-16 | Ferring B.V. | Procedimiento para la fabricación de degarelix y sus productos intermedios |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| CA2874927A1 (en) | 2012-06-01 | 2013-12-05 | Gregoire Schwach | Manufacture of degarelix |
| US8785426B1 (en) | 2013-12-13 | 2014-07-22 | Upsher-Smith Laboratories, Inc. | Testosterone gel compositions and related methods |
| EP3332787A4 (en) * | 2015-09-30 | 2018-08-01 | Fujifilm Corporation | Transdermally absorbable composition |
| WO2019088010A1 (ja) * | 2017-10-30 | 2019-05-09 | 帝國製薬株式会社 | 経皮投与製剤 |
| AU2019206552B2 (en) | 2018-01-10 | 2023-02-09 | Celista Pharmaceuticals Llc | Testosterone transdermal spray with film |
| CN109700764B (zh) * | 2019-02-20 | 2021-07-06 | 广东食品药品职业学院 | 双氢睾酮原位凝胶喷雾剂及其制备方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| DE2862341D1 (en) | 1977-12-26 | 1983-11-24 | Ihara Chemical Ind Co | Process for producing aromatic monocarboxylic acid |
| DK0593491T3 (da) | 1991-04-25 | 1997-03-17 | Romano Deghenghi | Luteiniseringshormonfrigørende hormonantagonistpeptider |
| ATE200428T1 (de) | 1992-02-12 | 2001-04-15 | Daikyo Gomu Seiko Kk | Medizinisches gerät |
| SI9300468A (en) | 1992-10-14 | 1994-06-30 | Hoffmann La Roche | Injectable composition for the sustained release of biologically active compounds |
| US5506207A (en) | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
| US5925730A (en) | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
| US5821230A (en) | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| FR2776520B1 (fr) | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20030139384A1 (en) * | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
| DE10107663B4 (de) * | 2001-02-19 | 2004-09-09 | Lts Lohmann Therapie-Systeme Ag | Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung |
| GB0117057D0 (en) | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| CN1411803A (zh) | 2002-08-29 | 2003-04-23 | 四川大学 | 制备前体脂质体的方法及其装置 |
| AR042815A1 (es) | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
| CN1997357A (zh) * | 2003-03-11 | 2007-07-11 | 安塔雷斯制药Ipl股份公司 | 透皮或透粘膜应用活性剂的用途和制剂 |
| US20050042268A1 (en) * | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| ATE534373T1 (de) * | 2003-10-10 | 2011-12-15 | Antares Pharma Ipl Ag | Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut |
| EP1634583A1 (en) * | 2004-09-09 | 2006-03-15 | Laboratoires Besins International | Testosterone gels comprising propylene glycol as penetration enhancer |
| EP1674082A1 (de) | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| JP5401092B2 (ja) * | 2005-06-03 | 2014-01-29 | アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド | 経皮的薬物送達のための方法および組成物 |
| CN101426475A (zh) * | 2006-04-21 | 2009-05-06 | 安塔雷斯制药Ipl股份公司 | 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法 |
| WO2007130809A2 (en) | 2006-05-06 | 2007-11-15 | Volodymyr Brodskyy | An automatic injectable drug mixing device |
| EP1891964A1 (en) | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
| EP1967202A1 (en) | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
| CN101754764A (zh) * | 2007-03-23 | 2010-06-23 | 优尼麦德药物股份有限公司 | 治疗小儿性腺机能减退的组合物和方法 |
| IL182922A0 (en) | 2007-05-02 | 2007-09-20 | Medimop Medical Projects Ltd | Automatic liquid drug reconstitution apparatus |
| TWI442932B (zh) | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法 |
| EP2257324B1 (en) | 2008-02-11 | 2016-07-27 | Safety Syringes, Inc. | Syringe with safety needle guard and clip to prevent release of guard during reconstitution process |
| CN102421414A (zh) | 2009-05-01 | 2012-04-18 | 辉凌公司 | 用于治疗前列腺癌的组合物 |
| TW201043221A (en) | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| US20120046264A1 (en) * | 2010-08-17 | 2012-02-23 | Biosante Pharmaceuticals, Inc. | Commercial scale production methods for transdermal hormone formulations |
| ES2617336T3 (es) | 2010-10-27 | 2017-06-16 | Ferring B.V. | Procedimiento para la fabricación de degarelix y sus productos intermedios |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| PL2731607T3 (pl) | 2011-07-15 | 2018-03-30 | Ferring B.V. | Sposób koordynacji czasu kolonoskopii, w którym podaje się kompozycję pikosiarczanową |
-
2012
- 2012-01-17 JO JOP/2012/0014A patent/JO3755B1/ar active
- 2012-01-18 SI SI201231641T patent/SI3072505T1/sl unknown
- 2012-01-18 MX MX2013008463A patent/MX340259B/es active IP Right Grant
- 2012-01-18 ES ES16169138T patent/ES2741744T3/es active Active
- 2012-01-18 US US13/979,881 patent/US8895053B2/en not_active Expired - Fee Related
- 2012-01-18 KR KR1020137020996A patent/KR101877476B1/ko active IP Right Grant
- 2012-01-18 DK DK16169138.1T patent/DK3072505T3/da active
- 2012-01-18 BR BR112013018951-7A patent/BR112013018951B1/pt active IP Right Grant
- 2012-01-18 JP JP2013550826A patent/JP6012632B2/ja not_active Expired - Fee Related
- 2012-01-18 CN CN201280006305.2A patent/CN103327962B/zh active Active
- 2012-01-18 HU HUE16169138 patent/HUE044327T2/hu unknown
- 2012-01-18 HU HUE12700406A patent/HUE027453T4/hu unknown
- 2012-01-18 RS RS20160495A patent/RS54898B1/sr unknown
- 2012-01-18 PT PT16169138T patent/PT3072505T/pt unknown
- 2012-01-18 RU RU2013133082A patent/RU2613891C2/ru active
- 2012-01-18 RS RS20190914A patent/RS59012B1/sr unknown
- 2012-01-18 WO PCT/EP2012/050695 patent/WO2012101016A1/en active Application Filing
- 2012-01-18 ES ES12700406.7T patent/ES2586122T3/es active Active
- 2012-01-18 PT PT127004067T patent/PT2667851T/pt unknown
- 2012-01-18 DK DK12700406.7T patent/DK2667851T3/en active
- 2012-01-18 PL PL12700406T patent/PL2667851T3/pl unknown
- 2012-01-18 CA CA2824941A patent/CA2824941A1/en not_active Abandoned
- 2012-01-18 LT LTEP16169138.1T patent/LT3072505T/lt unknown
- 2012-01-18 SI SI201230575A patent/SI2667851T1/sl unknown
- 2012-01-18 TR TR2019/09271T patent/TR201909271T4/tr unknown
- 2012-01-18 EP EP12700406.7A patent/EP2667851B1/en active Active
- 2012-01-18 PL PL16169138T patent/PL3072505T3/pl unknown
- 2012-01-18 AU AU2012210691A patent/AU2012210691B2/en active Active
- 2012-01-18 EP EP16169138.1A patent/EP3072505B1/en active Active
- 2012-01-19 TW TW101102189A patent/TWI564029B/zh not_active IP Right Cessation
- 2012-01-25 AR ARP120100241A patent/AR085090A1/es not_active Application Discontinuation
- 2012-01-25 SA SA112330224A patent/SA112330224B1/ar unknown
-
2013
- 2013-07-11 IL IL227454A patent/IL227454A/en active IP Right Grant
- 2013-07-25 ZA ZA2013/05665A patent/ZA201305665B/en unknown
-
2014
- 2014-05-30 HK HK14105154.5A patent/HK1192719A1/zh not_active IP Right Cessation
- 2014-10-22 US US14/520,706 patent/US20150110856A1/en not_active Abandoned
-
2016
- 2016-07-18 HR HRP20160887TT patent/HRP20160887T1/hr unknown
- 2016-08-09 JP JP2016156246A patent/JP2017019819A/ja not_active Withdrawn
-
2018
- 2018-08-27 HU HUS1800036C patent/HUS1800036I1/hu unknown
- 2018-10-11 LT LTPA2018516C patent/LTPA2018516I1/lt unknown
-
2019
- 2019-07-04 HR HRP20191216TT patent/HRP20191216T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085090A1 (es) | Formulacion transdermica de testosterona, metodo de tratamiento | |
| UY39192A (es) | Dispersión sólida, proceso para prepararla y forma de dosificación farmacéutica suministrable por vía oral que la comprende | |
| CL2013003163A1 (es) | Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion. | |
| BR112014031837A2 (pt) | formulações de progesterona | |
| JP2014503565A5 (es) | ||
| RU2016141135A (ru) | Трансдермальный крем | |
| AR085927A1 (es) | Composiciones farmaceuticas intranasales de benzodiazepina | |
| ECSP13012546A (es) | Formulación tópica para un inhibidor de jak | |
| MX2016015636A (es) | Formulaciones cannabinoides estables. | |
| AR087863A1 (es) | Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico | |
| CY1115991T1 (el) | Φαρμακευτικη ψεκαζομενη συνθεση που περιλαμβανει ενα αναλογο της βιταμινης d προϊον και ενα κορτικοστεροειδες | |
| CL2011001225A1 (es) | Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros. | |
| AR086409A1 (es) | Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino | |
| EA200801602A1 (ru) | Эмульсия | |
| ECSP12012252A (es) | Inhibición de irritación sensorial durante el consumo de productos de tabaco no fumables | |
| ECSP13013028A (es) | Cosmético | |
| AR074391A1 (es) | Composicion farmaceutica de un potente inhibidor de hcv para su administracion oral | |
| AR080491A1 (es) | Formulaciones orales y sales lipofilicas de metilnaltrexona | |
| HRP20141099T1 (hr) | Topiäśki pripravci za saäśuvanje ili ponovno uspostavljanje cjelovitosti sluznice | |
| PE20151326A1 (es) | Composiciones farmaceuticas que comprenden derivados de betulina | |
| BR112012031297A2 (pt) | formulações de spray oral e métodos para administração de sildenafil | |
| EA201490653A1 (ru) | Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств | |
| ECSP088889A (es) | Forma nueva de administración de racecadotril | |
| CR20140053A (es) | Formulaciones de ácido desoxicólico y sales del mismo | |
| WO2013009800A3 (en) | Compositions of alkylating agents and methods of treating skin disorders therewith |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |